Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

A Multicenter, Open-Label Feasibility Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105

Carlyn Rose Tan, MD, Stefan K. Barta, MD MRCP, MS, Shelly Y. Lensing, Ariela Noy, MD

Blood (2019) 134 (Supplement_1): 1595.

https://doi.org/10.1182/blood-2019-129702

Published: 2019

Journal Articles

Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy

Y. Lucy Liu, Yan Yan, Cody Webster, Lijian Shao, Shelly Y. Lensing, Hongyu Ni, Wei Feng, Natalia Colorado, Rupak Pathak, Zhifu Xiang, Martin Hauer-Jensen, Shaoguang Li, Daohong Zhou, Peter D. Emanuel

Blood (2016) 127 (15): 1912–1922.

https://doi.org/10.1182/blood-2015-05-646216

Published: 2016

Includes: Supplemental data

Journal Articles

Timing of the Loss of Pten Is Critical in Determining the Disease Phenotype in Mice- a Mouse Model for Pediatric Mixed MDS/MPN

Y. Lucy Liu, MD PhD, Yan Yan, MD, Cody Webster, BS, Lijian Shao, MD PhD, Shelly Y. Lensing, MS, Hongyu Ni, MD PhD, Wei Feng, MD, Daohong Zhou, MD, Zhifu Xiang, MD, Natalia Colorado, MD, Delli Robinson, Shaoguang Li, MD PhD, Peter D Emanuel, MD

Blood (2014) 124 (21): 3585.

https://doi.org/10.1182/blood.V124.21.3585.3585

Published: 2014

Journal Articles

Overexpression Of DNMT3a and DNMT3b Is Related To Downregulation Of Mir-29a In Juvenile Myelomonocytic Leukemia (JMML)

Y. Lucy Liu, MD, PhD, Shelly Y. Lensing, MS, Yan Yan, MD, Cody Webster, BS, Peter D. Emanuel, MD

Blood (2013) 122 (21): 4890.

https://doi.org/10.1182/blood.V122.21.4890.4890

Published: 2013

Journal Articles

Plasmablastic Lymphoma Is Curable The HAART Era. A 10 Year Retrospective By The AIDS Malignancy Consortium (AMC)

Ariela Noy, MD, Amy Chadburn, M.D., Shelly Y. Lensing, MS, Page Moore

Blood (2013) 122 (21): 1801.

https://doi.org/10.1182/blood.V122.21.1801.1801

Published: 2013

Journal Articles

Mir-183 Over-Expression: A Potential Biomarker for Juvenile Myelomonocytic Leukemia (JMML).

Y. Lucy Liu, MD, PhD, Yan Yan, MD, Shelly Y. Lensing, MS, Todd Cooper, DO, Peter D. Emanuel, MD

Blood (2012) 120 (21): 2558.

https://doi.org/10.1182/blood.V120.21.2558.2558

Published: 2012

Journal Articles

CREB Deficiency: A Potential Critical Factor for Selective GM-CSF Hypersensitivity in Juvenile Myelomonocytic Leukemia.

Y. Lucy Liu, MD, PhD, Priyangi A Malaviarachchi, BS, Shelly Y. Lensing, MS, Robert P. Castleberry, MD, Peter Dean Emanuel, MD

Blood (2009) 114 (22): 2604.

https://doi.org/10.1182/blood.V114.22.2604.2604

Published: 2009

NARROW

A Multicenter, Open-Label Feasibility Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105

Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy

Timing of the Loss of Pten Is Critical in Determining the Disease Phenotype in Mice- a Mouse Model for Pediatric Mixed MDS/MPN

Overexpression Of DNMT3a and DNMT3b Is Related To Downregulation Of Mir-29a In Juvenile Myelomonocytic Leukemia (JMML)

Plasmablastic Lymphoma Is Curable The HAART Era. A 10 Year Retrospective By The AIDS Malignancy Consortium (AMC)

Mir-183 Over-Expression: A Potential Biomarker for Juvenile Myelomonocytic Leukemia (JMML).

CREB Deficiency: A Potential Critical Factor for Selective GM-CSF Hypersensitivity in Juvenile Myelomonocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

A Multicenter, Open-Label Feasibility Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105

Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy

Timing of the Loss of Pten Is Critical in Determining the Disease Phenotype in Mice- a Mouse Model for Pediatric Mixed MDS/MPN

Overexpression Of DNMT3a and DNMT3b Is Related To Downregulation Of Mir-29a In Juvenile Myelomonocytic Leukemia (JMML)

Plasmablastic Lymphoma Is Curable The HAART Era. A 10 Year Retrospective By The AIDS Malignancy Consortium (AMC)

Mir-183 Over-Expression: A Potential Biomarker for Juvenile Myelomonocytic Leukemia (JMML).

CREB Deficiency: A Potential Critical Factor for Selective GM-CSF Hypersensitivity in Juvenile Myelomonocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only